These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

940 related articles for article (PubMed ID: 25998052)

  • 1. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
    Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
    J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
    Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
    Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
    J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model.
    Zalba S; Contreras AM; Merino M; Navarro I; de Ilarduya CT; Trocóniz IF; Koning G; Garrido MJ
    Nanomedicine (Lond); 2016; 11(5):465-77. PubMed ID: 26892017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
    Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
    Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR targeted thermosensitive liposomes: A novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery.
    Haeri A; Zalba S; Ten Hagen TL; Dadashzadeh S; Koning GA
    Colloids Surf B Biointerfaces; 2016 Oct; 146():657-69. PubMed ID: 27434152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
    Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
    Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.
    Tarpgaard LS; Christensen IJ; Høyer-Hansen G; Lund IK; Guren TK; Glimelius B; Sorbye H; Tveit KM; Nielsen HJ; Moreira JM; Pfeiffer P; Brünner N
    Int J Cancer; 2015 Nov; 137(10):2470-7. PubMed ID: 25664394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy.
    Corvo ML; Mendo AS; Figueiredo S; Gaspar R; Larguinho M; Guedes da Silva MF; Baptista PV; Fernandes AR
    Pharm Res; 2016 Jun; 33(6):1351-8. PubMed ID: 27033349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
    Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
    Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of therapeutic effectiveness of (131)I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer.
    Li W; Ji YH; Li CX; Liu ZY; Li N; Fang L; Chang J; Tan J
    World J Gastroenterol; 2016 Apr; 22(14):3758-68. PubMed ID: 27076760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
    Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
    Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.
    Zhang B; Wang T; Yang S; Xiao Y; Song Y; Zhang N; Garg S
    J Control Release; 2016 Sep; 238():10-21. PubMed ID: 27432750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Light induced cytosolic drug delivery from liposomes with gold nanoparticles.
    Lajunen T; Viitala L; Kontturi LS; Laaksonen T; Liang H; Vuorimaa-Laukkanen E; Viitala T; Le Guével X; Yliperttula M; Murtomäki L; Urtti A
    J Control Release; 2015 Apr; 203():85-98. PubMed ID: 25701610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells.
    Limasale YD; Tezcaner A; Özen C; Keskin D; Banerjee S
    Int J Pharm; 2015 Feb; 479(2):364-73. PubMed ID: 25595386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance.
    Liao ZX; Chuang EY; Lin CC; Ho YC; Lin KJ; Cheng PY; Chen KJ; Wei HJ; Sung HW
    J Control Release; 2015 Jun; 208():42-51. PubMed ID: 25637705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
    Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
    Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
    Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.